ADMA
HealthcareADMA Biologics, Inc. · Biotechnology · $2B
What is ADMA Biologics, Inc.?
ADMA Biologics is a biopharmaceutical company focused on plasma-derived therapies for immune deficiencies and infectious diseases, serving patients in the United States and internationally.
ADMA develops, manufactures, and markets specialty plasma-derived biologics. Revenue comes from selling IVIG products through specialty pharmacies, independent distributors, and alternate-site providers. The company also operates its own source plasma collection facilities, giving it direct control over a key input in its supply chain.
Incorporated in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics has built its business around specialty plasma collection and biologics manufacturing.
- BIVIGAM – IVIG treatment for primary humoral immunodeficiency
- ASCENIV – IVIG therapy for primary immunodeficiency
- Nabi-HB – hepatitis B immune globulin for acute exposure
- Pipeline immunoglobulin therapies targeting S. pneumoniae
Is ADMA a Good Stock to Buy?
UQS Score rates ADMA as Very Good overall.
The Quality and Risk pillars both score at the Strong level, reflecting disciplined operations and a manageable risk profile relative to sector peers. Growth also registers as Good, suggesting the business is expanding at a meaningful pace.
The Moat pillar sits at Neutral, indicating that competitive differentiation is present but not yet deeply entrenched compared to larger plasma biologics players.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ADMA pay dividends?
No — ADMA Biologics, Inc. does not currently pay a dividend.
ADMA Biologics does not currently pay a dividend. As a growth-oriented biopharmaceutical company, capital is directed toward expanding plasma collection capacity, commercializing existing products, and advancing pipeline candidates rather than returning cash to shareholders.
When does ADMA report earnings?
ADMA Biologics reports earnings on a quarterly cadence, typical for US-listed equities.
The company has demonstrated improving commercial traction across its IVIG product portfolio. Growth in product revenues has been supported by expanded distribution reach and increased plasma collection throughput.
For the most recent quarter's results, visit ADMA Biologics' investor relations page directly.
ADMA Price History
+516.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in ADMA Biologics, Inc.?
Based on ADMA Biologics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does ADMA Biologics do?
ADMA Biologics develops, manufactures, and markets plasma-derived biologics used to treat immune deficiencies and infectious diseases. Its commercial products include two IVIG therapies and a hepatitis B immune globulin. The company also runs its own plasma collection facilities to support supply.
Does ADMA pay dividends?
No, ADMA does not pay a dividend. The company reinvests available capital into product commercialization, plasma collection infrastructure, and pipeline development, which is common for growth-stage biopharmaceutical companies.
When does ADMA report earnings?
ADMA reports on a standard quarterly schedule. Specific upcoming dates are not confirmed in our data source. Check ADMA Biologics' investor relations page for the most current earnings calendar.
Is ADMA a good stock to buy?
UQS Score rates ADMA as Very Good, with Strong marks on both Quality and Risk pillars. Whether it fits your portfolio depends on your individual goals and risk tolerance. The full pillar breakdown is available to Pro members.
Is ADMA overvalued?
The UQS Valuation pillar for ADMA is rated Good, suggesting the stock is not trading at a significant premium relative to its fundamentals. Full valuation metrics are available inside the Pro dashboard.
What is ADMA's market cap bracket?
ADMA Biologics is classified as a mid-cap company. This places it in a tier where it has meaningful commercial scale but still carries more growth potential — and more volatility — than large-cap pharmaceutical peers.
Is ADMA a long-term quality stock?
From a quality indicator standpoint, ADMA's Strong Quality and Risk pillar ratings suggest a business with operational discipline. Long-term outcomes depend on pipeline execution and competitive dynamics in the plasma biologics market.
What sector does ADMA belong to?
ADMA Biologics operates in the Healthcare sector, specifically within the specialty biopharmaceutical and plasma-derived biologics segment. Explore other [healthcare stocks](/sector/healthcare) rated by UQS Score.
Unlock Full ADMA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access full financial metrics and trend data
- ✓Compare ADMA against sector peers on a standardized scoring framework
- ✓Get the complete analyst-style breakdown available to Pro members
Pro Analysis
ADMA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 70.0 | 95.1 | 46.0 | 77.3 | 87.0 | 68.4 | 0.0 |
| May 22, 2026 | 70.0 | 94.8 | 46.0 | 77.3 | 87.0 | 68.7 | 0.0 |
| May 21, 2026 | 70.0 | 94.6 | 46.0 | 77.3 | 87.0 | 68.8 | -4.0 |
| May 20, 2026 | 74.0 | 94.6 | 46.0 | 77.3 | 87.0 | 68.8 | +4.0 |
| May 17, 2026 | 70.0 | 95.1 | 46.0 | 77.3 | 87.0 | 68.6 | 0.0 |
| May 16, 2026 | 70.0 | 95.1 | 46.0 | 77.3 | 87.0 | 69.3 | 0.0 |
| May 14, 2026 | 70.0 | 94.8 | 46.0 | 77.3 | 87.0 | 69.9 | 0.0 |
| May 12, 2026 | 70.0 | 95.6 | 46.0 | 77.3 | 87.0 | 71.9 | 0.0 |
| May 11, 2026 | 70.0 | 95.2 | 46.0 | 77.3 | 87.0 | 71.5 | 0.0 |
| May 10, 2026 | 70.0 | 94.3 | 46.0 | 77.3 | 87.0 | 95.4 | 0.0 |
ADMA — Pillar Breakdown
Quality
— 95.1/100 (25%)ADMA Biologics, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 77.3/100 (20%)ADMA Biologics, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 87.0/100 (15%)ADMA Biologics, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 69.5/100 (15%)ADMA Biologics, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 46/100 (25%)ADMA Biologics, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ADMA.
Score Composition
Financial Data
More Stock Analysis
How is the ADMA UQS Score Calculated?
The UQS (Unified Quality Score) for ADMA Biologics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses ADMA Biologics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether ADMA Biologics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.